A promising anticancer drug, AMG 510, targets tumors caused by mutations in a signaling protein. The drug, which is currently in phase II clinical trials for efficacy, was developed by Amgen Inc. with the help of novel insights gained from protein structures solved at the ALS. https://als.lbl.gov/als-reveals-vulnerability-in-cancer-causing-protein/
January 2019 – July 2022
